

INTERVENTIONAL
VASCULAR
DIAGNOSTICS AND
THERAPY

SeQuent[®] Please OTW

PERIPHERAL DRUG COATED BALLOON CATHETER

SeQuent[®] Please OTW

PERIPHERAL DRUG COATED BALLOON CATHETER

The next level in treating peripheral stenoses

Following a path of sustained research and development in drug coated balloons SeQuent[®] Please OTW offers significant improvements in peripheral angioplasty.¹

DCB TREATMENT FOR ABOVE AND BELOW THE KNEE

- Leave nothing behind
- Effective and homogenous drug delivery into the vessel wall
- Long-term efficacy with short-term drug release
- Keep all therapeutical options
- No stent related complications

Paclitaxel with an effective drug dose of 3µg/mm²


- Effective drug dose in comparison to DCB with lower drug concentration²
- Homogeneous coating even in the balloon folds

¹ A Tepe, G. et al. *Cardiovasc Intervent Radiol* (2017). doi:10.1007/s00270-017-1713-2.

² "...standard dose (3.0-µg and 3.5µg) PCBs were significantly more effective compared with low-dose 2µg PCB in reducing both restenosis [...] and TLR [...]." Katsanos K et al. in *J Endovasc Ther*. 2016 Apr;23(2):356-70.

³ Ciccone G et al. in *Curr Med Chem*. 2013;20(10):1323-31.

⁴ Magyar K et al. *Clin Hemorheol Microcirc*. 2012;50(3):179-87.



A fruitful formulation: Paclitaxel & Resveratrol

SeQuent® Please OTW with its optimized and clinically proven¹ coating technology is made to facilitate easy and effective DCB use in daily practice.

Resveratrol as excipient with positive characteristics

- Naturally occurring, plant based substance
- Anti-inflammatory, antioxidant & anti-hypertensive^{3,4}
- Enables drug transfer into vessel wall

Consistent crystalline coating for your daily routine⁵

- High mechanical resistance of the coating
- Low drug loss in simulated use (<2%)
- Highly available drug dose after inflation

⁵ Data on file at B.Braun


SeQuent[®] Please OTW

PERIPHERAL DRUG COATED BALLOON CATHETER

CONSEQUENT Randomized Controlled Trial⁶

Study design & characteristics

- 153 patients
- Rutherford II-IV (95% Grade III-IV)
- Pre-procedure diameter stenosis: 76.6 % (\pm 18.1)
- TASC C+D lesions: 23.5 %
- Mean lesion length: 13.2 cm (\pm 10.4)
- Positive Remodeling (LLL <0.00mm) DCB group: 35.2 %
- Predilatation: 55.6 %
- Bailout stenting: 16.3 %



⁶ Tepe, G. et al. Cardiovasc Intervent Radiol (2017). doi:10.1007/s00270-017-1713-2.

⁷ Predilatation was only mandatory in total occlusions and even long & complex lesions were treated.

⁸ Schroder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278–286.

⁹ Werk M et al. Circ Cardiovasc Interv. 2012;5(6): 831–840.


¹⁰ Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1): 10–19.

¹¹ Zeller T et al. JACC Cardiovasc Interv. 2015;8(12): 1614–1622.

The safety and efficacy of SeQuent® Please OTW was investigated in real world conditions.⁷

Improving patients' quality of life

The CONSEQUENT randomized controlled trial demonstrated outstanding quality of life improvements for patients treated with SeQuent® Please OTW.



SeQuent® Please OTW

PRODUCT PORTFOLIO AND SPECIFICATIONS

SeQuent® Please OTW 035

Shaft length 75 cm	Shaft length 130 cm	Balloon diameter (mm)	Balloon length (mm)	Sheath compatibility (F)	Nominal pressure (atm)	Rated burst pressure (atm)
35040040	35340040	4.0	40	5	6	16
35140060	35340060	4.0	60	5	6	16
35140080	35340080	4.0	80	5	6	15
35140120	35340120	4.0	120	5	6	15
35140150	35340150	4.0	150	5	6	15
35150040	35350040	5.0	40	6	6	14
35150060	35350060	5.0	60	6	6	14
35150080	35350080	5.0	80	6	6	13
35150120	35350120	5.0	120	6	6	13
35150150	35350150	5.0	150	6	6	13
35160040	35360040	6.0	40	6	6	13
35160060	35360060	6.0	60	6	6	13
35160080	35360080	6.0	80	6	6	12
35160120	35360120	6.0	120	6	6	12
35160150	35360150	6.0	150	6	6	12
35170040		7.0	40	6	6	12
35170060		7.0	60	6	6	12
35180040		8.0	40	6	6	12
35180060		8.0	60	6	6	12

SeQuent® Please OTW 014


	Shaft length 130 cm	Balloon diameter (mm)	Balloon length (mm)	Sheath compatibility (F)	Nominal pressure (atm)	Rated burst pressure (atm)
	14215040	1.5	40	4	6	16
	14215080	1.5	80	4	6	16
	14215120	1.5	120	4	6	16
	14220040	2.0	40	4	6	16
	14220080	2.0	80	4	6	15
	14220120	2.0	120	4	6	15
	14220150	2.0	150	4	6	15
	14225040	2.5	40	4	6	16
	14225080	2.5	80	4	6	15
	14225120	2.5	120	4	6	15
	14225150	2.5	150	4	6	15
	14230040	3.0	40	4	6	16
	14230080	3.0	80	4	6	15
	14230120	3.0	120	4	6	15
	14230150	3.0	150	4	6	15

Technical specifications

Catheter type	OTW	Coating	Drug: Paclitaxel (concentration 3 µg/mm ²)
Shaft profile	035: 4.9F – 5.4F 014: 2.5F – 3.6F		Excipient: Resveratrol (plant based substance acts as hydrophilic spacer)
Lesion entry profile	035: 0.041" – 0.051" 014: 0.018"		Homogeneous coating even in the balloon folds exceeding distal and proximal markers
Radiopaque markers	2 markers (Platinum/Iridium)		Duration of inflated balloon: ≥ 30 seconds

B. Braun Vascular Systems

PORTFOLIO FOR PERIPHERAL DIAGNOSTICS AND THERAPY



Angiodyn® Procedure Kits



Celsite® Access Port Systems



Vascular Implants

Distributor

B. Braun Melsungen AG | Vascular Systems | Sieversufer 8 | 12359 Berlin | Germany
Phone +49 30 568207-300 | Fax +49 30 568207-210 | www.bbraun.com

Manufacturer acc. to MDD 93/42EG

B. Braun Melsungen AG | Carl-Braun-Str. 1 | 34212 Melsungen | Germany

The product trademarks "SeQuent", "VascuFlex", "Angiodyn" and "Celsite" are registered trademarks of B. Braun Melsungen AG.

Subject to technical changes. All rights reserved. This brochure may only be used for the exclusive purpose of obtaining information about our products. Reproduction in any form partial or otherwise is not permitted.